GSK plc - 20 May 2021 Form 4 Insider Report for Innoviva, Inc. (INVA)

Role
10%+ Owner
Signature
/s/ Victoria Whyte
Issuer symbol
INVA
Transactions as of
20 May 2021
Net transactions value
-$392,064,435
Form type
4
Filing time
24 May 2021, 17:04:29 UTC
Next filing
04 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INVA Common Stock Sale $392,064,435 -32,005,260 -100% $12.25 0 20 May 2021 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Common stock sold pursuant to a share repurchase agreement by and between Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, and Innoviva, Inc. (the "Issuer") dated as of May 20, 2021.
F2 Common Stock was held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person.